![]() |
市場調查報告書
商品編碼
1703398
冠狀動脈聚合物內支架市場-全球產業規模、佔有率、趨勢、機會和預測(按類型、應用、地區和競爭情況細分,2020-2030 年)Coronary Artery Polymer Endostents Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Application By Region & Competition, 2020-2030F |
2024 年全球冠狀動脈聚合物內支架市場價值為 48.2 億美元,預計在預測期內將實現穩定成長,到 2030 年的年複合成長率(CAGR) 為 5.20%。該市場代表了醫療保健行業內一個充滿活力且快速發展的領域,在冠狀動脈疾病 (CAD) 的治療中發揮關鍵作用。
市場概覽 | |
---|---|
預測期 | 2026-2030 |
2024年市場規模 | 48.2億美元 |
2030年市場規模 | 65.5億美元 |
2025-2030 年複合年成長率 | 5.20% |
成長最快的領域 | 聚乳酸 |
最大的市場 | 北美洲 |
冠狀動脈疾病的特徵是向心臟供血的動脈變窄,它仍然是全世界死亡和殘疾的主要原因。聚合物支架已成為一種變革性的解決方案,為傳統冠狀動脈繞道手術提供了微創替代方案。這些先進的醫療設備是由生物相容性聚合物製成的小型可擴展管,被插入阻塞或狹窄的冠狀動脈以恢復和維持血流。
由於不健康飲食、久坐行為和全球人口老化等生活方式因素,CAD 盛行率不斷上升,這是推動市場擴張的主要因素。聚合物內支架通常透過經皮冠狀動脈介入治療(PCI)進行部署,通常稱為血管成形術,與手術方法相比,它由於其效率高且恢復時間短而被廣泛採用。
技術創新繼續塑造這個市場,推動具有改進的藥物洗脫能力、生物可吸收材料和增強的輸送機制的下一代聚合物內支架的開發。這些進步旨在降低血管再狹窄(血管重新變窄)和血栓形成(血栓形成)的風險,同時支持更快的組織癒合和整合。此外,人們對心血管風險因素的認知不斷提高以及新興市場醫療保健基礎設施的加強也促進了該行業的全球擴張。
冠狀動脈疾病(CAD)盛行率上升
監管壁壘
微創手術的進展
The Global Coronary Artery Polymer Endostents Market was valued at USD 4.82 billion in 2024 and is projected to experience stable growth over the forecast period, with a compound annual growth rate (CAGR) of 5.20% through 2030. This market represents a dynamic and rapidly evolving segment within the healthcare industry, playing a critical role in the treatment of coronary artery disease (CAD).
Market Overview | |
---|---|
Forecast Period | 2026-2030 |
Market Size 2024 | USD 4.82 Billion |
Market Size 2030 | USD 6.55 Billion |
CAGR 2025-2030 | 5.20% |
Fastest Growing Segment | PLLA |
Largest Market | North America |
Coronary artery disease, characterized by the narrowing of the arteries that supply blood to the heart, continues to be a leading cause of death and disability worldwide. Polymer endostents have emerged as a transformative solution, offering a minimally invasive alternative to conventional coronary artery bypass surgery. These advanced medical devices-small, expandable tubes made from biocompatible polymers-are inserted into blocked or narrowed coronary arteries to restore and maintain blood flow.
The increasing prevalence of CAD, driven by lifestyle factors such as unhealthy diets, sedentary behavior, and an aging global population, is a primary factor fueling market expansion. Polymer endostents are typically deployed through percutaneous coronary intervention (PCI), commonly known as angioplasty, a widely adopted procedure due to its efficiency and shorter recovery times compared to surgical approaches.
Technological innovations continue to shape this market, leading to the development of next-generation polymer endostents with improved drug-eluting capabilities, bioabsorbable materials, and enhanced delivery mechanisms. These advancements are designed to reduce the risks of restenosis (vessel re-narrowing) and thrombosis (blood clot formation) while supporting faster tissue healing and integration. Additionally, rising awareness of cardiovascular risk factors and the strengthening of healthcare infrastructure in emerging markets are contributing to the sector's global expansion.
Key Market Drivers
Rising Prevalence of Coronary Artery Disease (CAD)
The growing incidence of CAD is a major driver behind the expansion of the Coronary Artery Polymer Endostents Market. CAD is the foremost cause of mortality globally, responsible for an estimated 17.9 million deaths annually-approximately 85% of which are due to heart attacks and strokes. According to the World Health Organization (WHO), addressing risk factors such as hypertension, obesity, and diabetes is essential to reducing premature deaths and alleviating the global healthcare burden caused by cardiovascular diseases.
In 2022, the estimated number of active CAD cases reached 315 million worldwide, highlighting the scale of this public health challenge. Sedentary lifestyles, poor dietary habits, smoking, and a rising incidence of comorbid conditions have all contributed to this increase. Consequently, there is a growing demand for effective and minimally invasive treatment options like coronary artery polymer endostents.
These stents offer a less invasive solution compared to traditional bypass surgery, functioning as internal scaffolds to keep arteries open while also delivering drugs that help prevent complications such as restenosis and thrombosis. Their use translates into shorter hospital stays, quicker recovery times, and fewer post-operative complications.
As healthcare systems increasingly focus on cost-effective and efficient treatment methods, polymer endostents are gaining favor for their clinical effectiveness and economic viability. Their minimally invasive nature aligns with the healthcare industry's shift toward outpatient care and same-day discharge protocols. Furthermore, the aging population-more vulnerable to CAD-underscores the importance of expanding access to such advanced treatment solutions.
Key Market Challenges
Regulatory Barriers
Despite significant technological progress and the increasing importance of polymer endostents in CAD management, the market faces several regulatory challenges that may impede growth. The medical device approval landscape is complex and varies significantly across global regions. Regulatory authorities such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other national bodies impose distinct and often rigorous requirements for market access.
This lack of regulatory harmonization results in extended approval timelines and elevated development costs. Manufacturers must navigate a demanding approval process, which includes extensive preclinical and clinical testing, as well as comprehensive documentation. Although these requirements ensure patient safety and product efficacy, they also delay commercialization and inflate operational expenses.
Moreover, regional discrepancies in regulatory expectations compel manufacturers to tailor their submissions for individual markets, adding further complexity to global expansion efforts. This fragmented regulatory landscape remains a key obstacle to the broader adoption and availability of coronary artery polymer endostents.
Key Market Trends
Advancement of Minimally Invasive Procedures
The increasing adoption of minimally invasive procedures is significantly contributing to the growth of the Coronary Artery Polymer Endostents Market. These approaches have revolutionized the treatment paradigm for CAD, offering both patients and providers a less intrusive and more efficient alternative to traditional surgery.
Polymer endostents are central to these procedures, deployed through catheter-based techniques rather than open-heart surgery. This method minimizes physical trauma, leading to less pain, reduced blood loss, and faster recovery. Patients benefit from shorter hospital stays and a quicker return to daily activities, ultimately improving quality of life.
Clinically, minimally invasive techniques enhance procedural precision, allowing cardiologists to navigate complex vascular anatomies with greater ease and safety. These procedures also tend to have fewer complications and shorter durations, making them increasingly attractive in busy healthcare settings.
The trend toward minimally invasive interventions, combined with ongoing product innovation and improved patient outcomes, is expected to continue propelling the coronary artery polymer endostents market forward.
In this report, the Global Coronary Artery Polymer Endostents Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in the Global Coronary Artery Polymer Endostents Market.
Global Coronary Artery Polymer Endostents market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report: